NDA 205750 · Mirum
Cholbam
Cholic Acid · Oral · Bile Acid
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 30, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Mar 17, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
183
45 Phase 3, 17 recruiting
FAERS reports
403
190 serious, 72 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 26, 2026.
CHOLBAM is a bile acid indicated for: • Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). ( 1.1 ) • Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. ( 1.2 ) Limitations of use: The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established. ( 1.3 ). 1.1 Bile Acid Synthesis Disorders Due to Single Enzyme Defects CHOLBAM is indicated for the treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). 1.2. Peroxisomal Disorders Including Zellweger Spectrum Disorders CHOLBAM is indicated for adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. 1.3. Limitations of Use The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established.
Mechanism: Cholic acid is a primary bile acid synthesized from cholesterol in the liver. In bile acid synthesis disorders due to SEDs in the biosynthetic pathway, and in PDs including Zellweger spectrum disorders, deficiency of primary bile acids leads to unregulated accumulation of intermediate bile acids and cholestasis. Bile acids facilitate fat digestion and absorption by forming mixed micelles and facilitate absorption of fat-soluble vitamins in the intestine. Endogenous bile acids including cholic acid enhance bile flow and provide the physiologic feedback inhibition of bile acid synthesis. The...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 17, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLabelLetter
2 products under this application
- CHOLBAM · CHOLIC ACID 50MG · CAPSULE, ORAL · Prescription
- CHOLBAM · CHOLIC ACID 250MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cholic Acid" as an intervention, any sponsor and status, largest first.
- Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by StatinPivotal-lookingStatus unknown
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT05500937 · 1,000 participants (planned) · Start Mar 1, 2021 · Primary completion Dec 31, 2023
Drug: UDCA · For: Diabetes Mellitus
Sites: Xi’an, China
- MITE in the Treatment of Dyspepsia After CholecystectomyPivotal-lookingStatus unknown
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT04786795 · 990 participants (planned) · Start Mar 1, 2021 · Primary completion Feb 1, 2022
Drug: Compound Azintamide Enteric-coated Tablets; Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets · For: Patients With Dyspeptic Symptoms After Cholecystectomy
- Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis CPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00200343 · 596 participants · Start Jul 2002
Drug: Ursodeoxycholic acid 150mg / day; Ursodeoxycholic acid 600mg / day and 1 more · For: Chronic Hepatitis C
Sites: Hongo, Bunkyo-ku, Tokyo, Japan
- Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental AreaPivotal-lookingCompleted
Kythera BiopharmaceuticalsIndustry
NCT01546142 · 516 participants · Start Mar 2012 · Primary completion May 2013
Drug: Deoxycholic acid injection; Placebo · For: Moderate or Severe Submental Fullness
Sites: Little Rock, Arkansas; Beverly Hills, California; Los Angeles, California · 35 sites in all
- Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental AreaPivotal-lookingCompleted
Kythera BiopharmaceuticalsIndustry
NCT01542034 · 506 participants · Start Feb 2012 · Primary completion May 2013
Drug: Deoxycholic acid injection; Placebo · For: Moderate or Severe Submental Fullness
Sites: Birmingham, Alabama; Beverly Hills, California; Irvine, California · 36 sites in all
- Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac SurgeryPivotal-lookingCompleted
China National Center for Cardiovascular DiseasesGovernment (non-federal)
NCT05690646 · 491 participants · Start Jan 28, 2023 · Primary completion Mar 24, 2023
Drug: Nirmatrelvir/ritonavir; Ursodeoxycholic acid · For: Cardiac Surgery
Sites: Beijing, China
- Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished ChildrenPivotal-lookingStatus unknown
University of OxfordAcademic, hospital or other
NCT04542473 · 400 participants · Start Jul 1, 2021 · Primary completion Oct 31, 2023
Drug: Pancreatic Enzyme; Ursodeoxycholic acid · For: SEPSIS; MALNUTRITION, CHILD
Sites: Dhaka, Bangladesh; Kilifi, Kenya; Blantyre, Malawi · 4 sites in all
- Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVRPivotal-lookingCompleted
Zagazig UniversityGovernment (non-federal)
NCT03659058 · 400 participants · Start Mar 2, 2016 · Primary completion Aug 2018
Drug: silymarin; Ursodeoxycholic Acid and 2 more · For: Fibrosis, Liver
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea58
- death40
- vomiting29
- pyrexia21
- seizure20
- constipation19
- aspartate aminotransferase increased18
- alanine aminotransferase increased17
- disease progression16
- abdominal pain13
- cough13
- nasopharyngitis13
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2015 | 3 |
| 2016 | 20 |
| 2017 | 18 |
| 2018 | 40 |
| 2019 | 43 |
| 2020 | 47 |
| 2021 | 39 |
| 2022 | 31 |
| 2023 | 115 |
| 2024 | 28 |
| 2025 | 9 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cholbam (Cholic Acid)
2024 spending
$5.9M
Beneficiaries
n/a
78 claims
Per beneficiary
n/a
$849.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,701,830 |
| 2021 | $3,358,341 |
| 2022 | $3,638,799 |
| 2023 | $4,476,517 |
| 2024 | $5,938,533 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Exercise Training Independent of Intensity Lowers Plasma Bile Acids in Prediabetes.
Malin SK, Syeda USA · Med Sci Sports Exerc 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- The clinical and biochemical effectiveness and safety of cholic acid treatment for bile acid synthesis defects: a systematic review.
Polak Y, van Dussen L, Kemper EM, et al. · Orphanet J Rare Dis 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Influence of the bile acid/microbiota axis in ileal surgery: a systematic review.
Senanayake T, Makanyengo S, Hoedt EC, et al. · Colorectal Dis 2024 · Systematic Review
- Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study.
Levy C, Caldwell S, Mantry P, et al. · Clin Transl Gastroenterol 2024 · Clinical Trial, Phase I, Multicenter Study
- [Cholagenic diarrhea].
Parfenov AI, Krums LM, Lychkova AE, et al. · Ter Arkh 2008 · Clinical Trial, Comparative Study
- Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study.
Fabris P, Tositti G, Mazzella G, et al. · Aliment Pharmacol Ther 1999 · Clinical Trial, Randomized Controlled Trial
Sponsor: Mirum
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.